1
|
Tao R, Liu L, Xiong Y, Zhang Q, Lv X, He L, Ren F, Zhou L, Chen B, Wu K, Zhang Y, Chen H. Construction and evaluation of a phospholipid-based phase transition in situ gel system for brexpiprazole. Drug Deliv Transl Res 2023; 13:2819-2833. [PMID: 37160629 DOI: 10.1007/s13346-023-01349-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/06/2023] [Indexed: 05/11/2023]
Abstract
The objective of this study was to develop phospholipid-based injectable phase transition in situ gels (PTIGs) for the sustained release of Brexpiprazole (Brex). Phospholipid (Lipoid S100, S100) and stearic acid (SA) were used as the gel matrix which was dissolved in biocompatible solvent medium-chain triglyceride (MCT), N-methyl pyrrolidone (NMP), and ethanol to obtain PTIGs solution. The Brex PTIG showed a solution condition of low viscosity in vitro and was gelatinized in situ in vivo after subcutaneous injection. Both in vitro release assay and in vivo pharmacokinetics study in SD rats displayed that Brex in PTIGs could achieve a sustained release, compared with brexpiprazole solution (Brex-Sol) or brexpiprazole suspension (Brex-Sus). The Brex-PTIGs had good degradability and biocompatibility in vivo with rare inflammation at the injection site. Among the three Brex-PTIG formulations, Brex-PTIG-3 with the SA in the formulation had the greatest gelation viscosity, the lowest initial release rate, and the most stable release profile with sustained release of up to 60 days. The above results indicated that, as a novel drug delivery system, the Brex-PTIGs offered a new option for the clinical treatment of patients with schizophrenia.
Collapse
Affiliation(s)
- Ran Tao
- College of Pharmacy, Chongqing Medical University, Chongqing, 400042, China
| | - Li Liu
- Yaopharma Co, Ltd, No. 100, Xingguang Ave, Chongqing, 401121, China
| | - Yingxin Xiong
- Yaopharma Co, Ltd, No. 100, Xingguang Ave, Chongqing, 401121, China
| | - Qianyu Zhang
- College of Pharmacy, Chongqing Medical University, Chongqing, 400042, China
| | - Xiangyu Lv
- Yaopharma Co, Ltd, No. 100, Xingguang Ave, Chongqing, 401121, China
| | - Linbo He
- Yaopharma Co, Ltd, No. 100, Xingguang Ave, Chongqing, 401121, China
| | - Fang Ren
- College of Pharmacy, Chongqing Medical University, Chongqing, 400042, China
| | - Lu Zhou
- College of Pharmacy, Chongqing Medical University, Chongqing, 400042, China
| | - Baoyan Chen
- College of Pharmacy, Chongqing Medical University, Chongqing, 400042, China
| | - Kexin Wu
- College of Pharmacy, Chongqing Medical University, Chongqing, 400042, China
| | - Yan Zhang
- Yaopharma Co, Ltd, No. 100, Xingguang Ave, Chongqing, 401121, China.
| | - Huali Chen
- College of Pharmacy, Chongqing Medical University, Chongqing, 400042, China.
| |
Collapse
|
2
|
Zhou H, Xie J, Zhu X, Li X, Yu X, Zhang Y, Su Y, He C, Zhu M, Li XL, Liu Y, Chen J, Cheng D, Chen M, Wang Y, Ge Q, Fan L, Wang Y, Shao Z, Liu B, Shan R, Dai X, Wang H, Wang H. Pharmacokinetic and pharmacodynamic evaluation of the new prolonged-release leuprorelin acetate microspheres for injection compared with Enantone® in healthy Chinese male volunteers. Expert Opin Drug Metab Toxicol 2021; 17:1149-1156. [PMID: 34372746 DOI: 10.1080/17425255.2021.1948534] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
PURPOSE To compare the pharmacokinetics, pharmacodynamics and safety of the new prolonged-release leuprorelin acetate microspheres for injection (3.75 mg) with the reference product Enantone® (3.75 mg). METHOD 48 healthy male volunteers were enrolled and randomly received a single 3.75 mg dose of the test drug or Enantone®. RESULTS There were no significant differences in Cmax, AUC0-t and AUC0-48 between the test group and reference group (P > 0.05). The 90% confidence intervals of the two groups were 87.49%~112.74%, 97.15%~154.25%, and 80.85%~109.01%, respectively. Twenty-eight days after administration, both groups reached 100.0% castration level; there was no difference in the time from administration to reaching castration level between the two groups (P > 0.05); However, the difference between the two groups in the duration of castration level was statistically significant (P < 0.05). There were no major or serious adverse events, and the severity was mild to moderate. CONCLUSION The pharmacokinetic characteristics of leuprorelin in two groups were consistent. The two groups exhibited similar inhibitory effects on testosterone and more subjects in the test group maintained a longer castration time than those in the reference group.
Collapse
Affiliation(s)
- Huan Zhou
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.,School of Pharmacy, Bengbu Medical University, Bengbu, Anhui, China.,School of Public Foundation, Bengbu Medical University, Bengbu, Anhui, China
| | - Jing Xie
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| | - Xingyu Zhu
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.,School of Pharmacy, Bengbu Medical University, Bengbu, Anhui, China
| | - Xiaoyi Li
- Zhaoke Pharmaceutical (Hefei) Co., Ltd, Hefei, Anhui, China
| | - Xiaohui Yu
- Zhaoke Pharmaceutical (Hefei) Co., Ltd, Hefei, Anhui, China
| | - Yong Zhang
- Zhaoke Pharmaceutical (Hefei) Co., Ltd, Hefei, Anhui, China
| | - Yue Su
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.,School of Public Foundation, Bengbu Medical University, Bengbu, Anhui, China
| | - Cuixia He
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.,School of Pharmacy, Bengbu Medical University, Bengbu, Anhui, China
| | - Minhui Zhu
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.,School of Pharmacy, Bengbu Medical University, Bengbu, Anhui, China
| | - Xiao Li Li
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| | - Yuanyuan Liu
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| | - Juan Chen
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| | - Dongmei Cheng
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| | - Mengmeng Chen
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| | - Ying Wang
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| | - Qin Ge
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| | - Ling Fan
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| | - Ying Wang
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| | - ZhongHuan Shao
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| | - Bingyan Liu
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| | - Rongfang Shan
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| | - Xiangrong Dai
- Zhaoke Pharmaceutical (Hefei) Co., Ltd, Hefei, Anhui, China
| | - Hongju Wang
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| | - Huaxue Wang
- First-in-Human Clinical Trial Wards in the National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.,Department of Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| |
Collapse
|
4
|
Dal Col LSB, Andrade DL, Gon LM, Capibaribe DM, Amaro MP, Truzzi NCC, Malkomes BR, Reis LO. Perception of castration value over cost in the metastatic prostate cancer scenario: a contemporary pharmacoeconomic perspective. Int Braz J Urol 2021; 48:175-179. [PMID: 34115454 PMCID: PMC8691248 DOI: 10.1590/s1677-5538.ibju.2021.0258] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2021] [Accepted: 04/10/2021] [Indexed: 11/22/2022] Open
Affiliation(s)
- Luciana Saboya Brito Dal Col
- UroScience, Universidade Estadual de Campinas - UNICAMP, Campinas, SP, Brasil.,Departamento de Urologia, Pontifícia Universidade Católica de Campinas - PUC - Campinas, Campinas, SP, Brasil
| | - Danilo L Andrade
- UroScience, Universidade Estadual de Campinas - UNICAMP, Campinas, SP, Brasil
| | - Lucas M Gon
- UroScience, Universidade Estadual de Campinas - UNICAMP, Campinas, SP, Brasil
| | - Diego M Capibaribe
- UroScience, Universidade Estadual de Campinas - UNICAMP, Campinas, SP, Brasil
| | - Marcelo P Amaro
- UroScience, Universidade Estadual de Campinas - UNICAMP, Campinas, SP, Brasil.,Departamento de Urologia, Pontifícia Universidade Católica de Campinas - PUC - Campinas, Campinas, SP, Brasil
| | - Natássia C C Truzzi
- UroScience, Universidade Estadual de Campinas - UNICAMP, Campinas, SP, Brasil
| | - Barbara R Malkomes
- UroScience, Universidade Estadual de Campinas - UNICAMP, Campinas, SP, Brasil.,Departamento de Urologia, Pontifícia Universidade Católica de Campinas - PUC - Campinas, Campinas, SP, Brasil
| | - Leonardo O Reis
- UroScience, Universidade Estadual de Campinas - UNICAMP, Campinas, SP, Brasil.,Departamento de Urologia, Pontifícia Universidade Católica de Campinas - PUC - Campinas, Campinas, SP, Brasil
| |
Collapse
|